LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,000 | -5.0% | 16,602 | +16.6% | 0.00% | – |
| Q2 2023 | $20,000 | +900.0% | 14,234 | +1110.4% | 0.00% | – |
| Q1 2023 | $2,000 | – | 1,176 | +253.2% | 0.00% | – |
| Q4 2022 | $0 | -100.0% | 333 | -89.1% | 0.00% | – |
| Q3 2022 | $3,000 | -62.5% | 3,054 | -41.3% | 0.00% | – |
| Q2 2022 | $8,000 | -38.5% | 5,204 | -38.6% | 0.00% | – |
| Q1 2022 | $13,000 | -81.7% | 8,476 | -70.7% | 0.00% | – |
| Q4 2021 | $71,000 | +73.2% | 28,963 | +77.8% | 0.00% | – |
| Q3 2021 | $41,000 | +57.7% | 16,293 | +79.3% | 0.00% | – |
| Q2 2021 | $26,000 | +136.4% | 9,088 | +97.0% | 0.00% | – |
| Q1 2021 | $11,000 | -15.4% | 4,613 | -41.2% | 0.00% | – |
| Q4 2020 | $13,000 | +62.5% | 7,842 | -2.4% | 0.00% | – |
| Q3 2020 | $8,000 | -20.0% | 8,037 | -29.1% | 0.00% | – |
| Q2 2020 | $10,000 | +233.3% | 11,338 | +268.6% | 0.00% | – |
| Q1 2020 | $3,000 | -66.7% | 3,076 | -68.4% | 0.00% | – |
| Q4 2019 | $9,000 | +12.5% | 9,743 | +21.8% | 0.00% | – |
| Q3 2019 | $8,000 | – | 7,998 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
| Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
| Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
| Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
| DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
| Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
| Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
| XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
| Ergoteles LLC | 490,895 | $555,000 | 0.02% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |